The Zhitong Finance App learned that on August 17, AstraZeneca (AZN.US) announced the official launch of tezelizumab injections in China. Tezelizumab is a biologic agent that treats severe asthma and breaks through phenotypic and biomarker level limits, and targets thymic stromal lymphopoietin (TSLP).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.